Zhengtao Li

Zhengtao Li

Auto-generated profile, based on publicly available information

Zhengtao Li

School of Electronic and Communication Engineering, Tianjin Normal University, Tianjin, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in IEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing
Verified
Journal Article
Open access
ZLZhengtao Li
Zhengtao Li
GCGuokun Chen
Guokun Chen
TZTianxu Zhang
Tianxu Zhang

28 August 2018 in Infrared Physics & Technology
Verified
Journal Article
Closed access
Zhenghua HuangZhenghua Huang
Zhenghua Huang
ZWZhicheng Wang
Zhicheng Wang
QLQian Li
Qian Li
ZLZhengtao Li
Zhengtao Li
TZTianxu Zhang
Tianxu Zhang
YLYongjiu Li
Yongjiu Li

3 September 2019 in IEEE Access
Verified
Journal Article
Open access
ZLZhengtao Li
Zhengtao Li
GCGuokun Chen
Guokun Chen
TZTianxu Zhang
Tianxu Zhang

8 December 2025
Verified
Conference Paper
Closed access
PHPeng Hu
Peng Hu
ZLZhengTao Li
ZhengTao Li
LLLuLu Li
LuLu Li
For the factual accuracy evaluation of long text in large language models, existing methods rarely reflect the completeness of long text knowledege. In this paper, we propose a complete method for evaluating the factual accuracy. The kernel of this method is to generate a complete evaluation question set of factual long texts, We provide a pipelined method to achieve this process by traversing the Abstract Meaning Representation(AMR) graph. On our data set, ChatGPT-4 and Deepseek maintain an average error rate of 5.18% and 3.81%, respectively. The evaluation contributes to a more comprehensive understanding of the factual accuracy of language models, and expected to be embedded in the evaluation of large-scale factual knowledge.

4 April 2023 in Cancer Research
Verified
Journal Article
Open access
CYCuiqing Yang
Cuiqing Yang
YWYifang Wang
Yifang Wang
TLTingting Liu
Tingting Liu
FJFuwei Jiang
Fuwei Jiang
Chao WangChao Wang
Chao Wang
ZCZhuoxiao Cao
Zhuoxiao Cao
Introduction: Chimeric antigen receptor (CAR) T-cell therapy is an emerging therapeutic option for cancer treatment. However, its efficacy is limited, especially in solid tumors. This is partly because the CAR T cells become dysfunctional and exhausted in the tumor microenvironment. However, the key pathways responsible for impaired function of exhausted T cells remain unclear. Immunosuppressive cytokines or checkpoint proteins like TGF-β and PD-L1, are overproduced, which may lead to the downregulation of CD8+ T cell action and the promotion of T-reg maturation. E3 ligase Casitas B-Lineage Lymphoma Proto-Oncogene B (CBL-B) is a key negative modulator of T/NK-cell receptor and co-stimulatory regulation. CBL-B inhibition lowers the threshold of antigen-specific T/NK cell activation, even in absence of co-stimulatory signaling or the presence of an immune suppressive environment. Genetic ablation of CBL-B or functional inactivation of its E3 ligase activity in mice or primary human T cells enhances immune-mediated tumor growth control. Therefore, CBL-B inhibition may address the suboptimal response to current immunotherapies due to low inflammation, no/low co-stimulation signal or a high immune suppressive environment. Several groups demonstrated that deficiency of CBL-B overcomes endogenous CD8+ T-cell exhaustion, and deletion of CBL-B in CAR-T cells renders them resistant to exhaustion and deletion of CBL-B in CAR-NK cells provides greater resistance to TGF-β. Methods: We tested the CAR expression, T/NK cell activation and in vitro cytotoxicity when ex vivo culture of CAR-T or CAR-NK cells with CBL-B inhibitors. Results: We demonstrated that the combination of CBL-B inhibitor and CAR-NK cells elicited remarkable persistence in multiple runs of repeated cancer cell clearance assay, as compared to CAR-NK cells alone. Moreover, the combination of CAR-NK cells with both anti-PDL1-IL15 and CBL-B inhibitor showed further increased persistence in repeated cancer cell clearance assay. Conclusions: preclinical data provided evidence of CBL-B inhibitors to enhance key parameters associated with T/NK cell activation and reduce susceptibility to immune suppression. Our results suggest the combination strategy of cell therapy and immune regulating small/large molecule therapy might achieve better anti-tumor efficacy in both hematological and solid tumors. Citation Format: Cuiqing Yang, Yifang Wang, Tingting Liu, Fuwei Jiang, Chao Wang, Qingyang Wang, Qin Wang, Zhengtao Li, Wansun Mai, Gang Ye, Renhong Tang, Zhuoxiao Cao. Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2899.

14 February 2020
Verified
Conference Paper
Closed access
ZLZhengtao Li
Zhengtao Li
ZWZhongyang Wang
Zhongyang Wang
HXHai Xu
Hai Xu
YZYaozong Zhang
Yaozong Zhang
TZTianxu Zhang
Tianxu Zhang
SPIE Digital Library Proceedings